Why is "Lipoprotein(a)" trending?

Search Interest Perspective

• Cholesterol drug setback casts doubt over multibillion-dollar race - CNBC
• Doctors thought this heart breakthrough was coming. Then everything changed - Cleveland.com
• Q&A: Sinikka Green, MD: Medical Director at Care Access talks about free heart attack risk insights - VEGAS INC
• Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons - BioSpace
• Cardiologists expected this new drug to prevent heart attacks—so why did it fail? - Medical Xpress
• The Most Promising New Drug for Lowering a Dangerous Type of Cholesterol Didn’t Work. Now What? - Men's Health
• How Novartis' Double-Stacked Failures Shook Biotech - Investor's Business Daily
• Another Heart Drug Fails, Shocking Cardiologists - The New York Times
• Novartis’ Lipoprotein(a) Drug Pelacarsen Fails Phase III Trial - GenomeWeb
• First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection - Cleveland Clinic
• Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps - The American Journal of Managed Care
• Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines - BioPharma Dive
• ‘Lipoprotein a’ levels, a hidden risk for heart disease, determined by genetics - uclahealth.org
• Livedoid Vasculopathy in a Young Woman With Elevated Factor VIII and Lipoprotein(a): A Case Report With Consideration of Future Pregnancy - Cureus
• Pelacarsen Fails to Meet Primary Endpoint in Phase 3 Lp(a) Trial - The Clinical Trial Vanguard
• Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial - Fierce Biotech
• Researchers test the cholesterol-lowering power of new drugs that may help people who have greater genetic risks for heart disease - UCHealth
• Phenotypic clustering identifies heterogeneous cardiovascular risk among patients with elevated lipoprotein(a) - Nature
• Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal - WSJ
• New treatments for common cardiovascular risk factor near the market, with billions at stake - STAT
• Lp(a)HORIZON: Top-line Results Dash Hopes for Pelacarsen - TCTMD.com
• Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial - American Heart Association Journals
• ZEUS And Lp(a)HORIZON: Biomarkers Vs. Cardiovascular Outcomes - Forbes
• Novel siRNA Produces Deep, Durable Reduction in Lp(a) - Cleveland Clinic
• Novartis Lp(a) Drug Failure Raises Questions for Targeting Cardiovascular Biomarker - GenomeWeb
• The sneaky kind of cholesterol that may be threatening your heart health - The Washington Post
• Novartis cholesterol setback tests hopes for emerging heart disease drugs - Reuters
• Should I Get a Lipoprotein (a) Test? - Mass General Brigham
• Oxidized Phospholipids Track Closely With Lp(a) Reductions in Clinical Trial - Cleveland Clinic
• Novartis hit as Lp(a) drug fails cardio outcomes trial - pharmaphorum
• Pathogenic interplay between markedly elevated plasma lipoprotein(a) levels and prothrombotic mechanisms: a case report - Frontiers
• A multi-method study on GPs’ perspectives on Lipoprotein(a) as an actionable cardiovascular risk factor - Frontiers
• Why PCPs Should Check Lipoprotein(a) - Medscape
• High lipoprotein(a) levels linked with long-term heart disease risk - Medical News Today
• Very High Lipoprotein(a) Flags 30‑Year CVD Risk Among Healthy Women - Physician's Weekly
• Novartis announces Lp(a)HORIZON Phase III topline results - GlobeNewswire
• Lipoprotein(a) and oxidized phospholipids are associated with myocardial inflammation after acute myocardial infarction - Nature
• Novartis, Ionis' experimental heart drug misses key goal in closely watched trial - Reuters
• Premature Coronary Artery Disease in a Young Female Patient With High Lipoprotein(a): - JACC Journals
• Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) - Business Wire
• Relationship between lipoprotein(a) and PCSK9 in angiogram-proven premature coronary artery disease in an Asian cohort - Nature
• Simple blood test can signal a silent genetic risk factor for heart disease, according to Emory cardiologists - Emory News
• Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon - The American Journal of Managed Care
• Higher Lp(a) Threshold More Closely Linked to Major ASCVD Events - TCTMD.com
• Lp(a) and CAC Levels Independently Predict Long-term ASCVD Risk - TCTMD.com
• Utility of Serum Homocysteine and Lipoprotein(a) in Acute Coronary Syndrome: A Cross-Sectional Study From Western India - Cureus
• Response by Bhatia and Tsimikas to Letter Regarding Article, “Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Medicated Cardiovascular Risk: A Participant-Level Meta-Analysis” - American Heart Association Journals
• Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction - Frontiers
• ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - www.heart.org
• Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome - American Heart Association Journals
• Feature | Lipoprotein(a): An Independent Risk Factor For CV Disease - acc.org
• Counseling Patients on the New Cholesterol Guideline: What Providers Should Know - Cleveland Clinic
• New cholesterol guidelines recommend Lp(a) blood test - Harvard Health
• Genetically Predicted Levels of Lipoprotein(a) and Risk of Cerebrovascular Disease - American Heart Association Journals
• Novartis, Ionis’ experimental heart drug misses key goal in closely watched trial - WTVB
• Susan’s Story: I Never Imagined I’d Be Someone Who Had a Heart Attack - Novartis
• High Lp(a) Identifies Residual Cardiovascular Risk - Medscape
• FDA Clears New Heart Disease Risk Test for Clinical Labs - Clinical Lab Products
• Lipoprotein(a) linked to elevated cardiovascular risk despite standard treatment - EurekAlert!
• Expert Insights: Lp(a) and ApoB in the 2026 Dyslipidemia Guidelines - HCPLive
• Lipoprotein(a) and Long-Term Heart Risks: Study Makes the Case for Screening - MedPage Today
• Elevated Lipoprotein(a) and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Systematic Review - Cureus
• 1 Test Can Detect Your Hidden Risk for a Heart Attack, Even if You're Healthy - TODAY.com
• Few Prescribing for Elevated Lp(a) in Low-Risk Patients - Medscape
• Clinical significance of lipoprotein(a) as a residual risk factor for atherosclerotic coronary plaque progression in statin-treated patients with coronary artery disease - Nature
• LP(a) screening may help detect inherited heart disease risk - WTAE
• Metabolic implications of COVID-19 with a focus on lipid profiles and inflammatory markers - Nature
• New Cholesterol Guidelines Recommend 3 Tests That Can Better Predict Heart Disease Risk - Verywell Health
• IL-6, Not hsCRP, Modified Lp(a)-Associated CAD Risk - The American Journal of Managed Care
• Low Lipoprotein(a) Harm; Soccer Pro Collapses Again; Cancer-Related Ischemic Stroke? - MedPage Today
• Lipoprotein(a) Levels Matter Even in Primary Prevention - Medscape
• Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis - American Heart Association Journals
• More Than 5 Million US Adults Could Benefit From Lp(a)-Targeted Therapies - The American Journal of Managed Care
• A cholesterol test you've never heard of is now recommended to prevent heart disease - NPR
• Lp(a) Linked to 30-Year CVD Risk in Healthy Women - TCTMD.com
• Chest Pain and Hidden Genetic Risk: A Case Report on the Role of Elevated Lipoprotein(a) in Early Cardiovascular Disease - Cureus
• Very High Lipoprotein(a) Levels Linked to Cardiovascular Disease Among Healthy Women - HCPLive
• Lipoprotein(a) Screening Proposed for Healthy Women - Inside Precision Medicine
• Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies - springermedicine.com
• Lipoprotein(a) Lowering Therapies Market : Global Industry Analysis and Opportunity Assessment, 2036 - Future Market Insights
• Case Report: Elevated Lp(a) as a cause of severe ASCVD in a healthy veteran athlete with low calculated QRISK3 score - Frontiers
• New therapies on the way to lower Lp(a), a cardiovascular risk factor - Managed Healthcare Executive
• The Genetic Puzzle of Heart Disease: Inside Amgen’s Commitment to Lp(a) - Amgen
• What the New Cholesterol Guidelines Mean for Your Health - Katie Couric Media
• New cholesterol guidelines: 5 takeaways from a cardiologist who helped write them - UChicago Medicine
• A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques - Nature
• Study Shows Strong Association Between Long-Term CVD Risk and High Lipoprotein(a) Levels in Women - Medscape
• Resmetirom Cuts CV Risk in MASH: Meena Bansal, MD - The American Journal of Managed Care
• 1 reason why healthy people have heart attacks, and what experts say could help - CBC
• Hidden Heart Risk Found in 1 in 5 People, Study Warns - SciTechDaily
• Confused About the New Cholesterol Guidelines? Here’s What to Know. - The New York Times
• Prevalence of elevated lipoprotein(a) in individuals with inflammatory bowel disease: Potential implications for cardiovascular risk | Medicina Clínica (English Edition) - www.elsevier.com
• Lipoprotein(a): Actionable today, treatable tomorrow? - Royal Australian College of General Practitioners (RACGP)
• Extremely elevated lipoprotein(a) levels tied to 30-year heart risk in women - Medical Xpress
• 5 takeaways from the new cholesterol guidelines - Northside Hospital
• The lower the better, for longer time: new cholesterol guidelines are a “paradigm shift” in preventing heart disease - National Academy of Medicine
• Quest for a drug that lowers an artery-clogging particle nears finish line - The Washington Post
• 'It’s going to be huge': The 'diabolical' molecule poised to become biotech's next gold rush - Fierce Biotech
• 'The highlight of my career': MUSC specialists help set national lipid, cholesterol recommendations - The Medical University of South Carolina
• ‘Excitement and interest’ as Lp(a) therapies inch closer - Healio